Toby Gould

Toby Gould

Auto-generated profile, based on publicly available information

Toby Gould

Children's Brain Tumour Research Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ASand Stuart Smith
and Stuart Smith
BTBetty M. Tyler
Betty M. Tyler
TGToby Gould
Toby Gould
Northern Institute for Cancer ResearchNorthern Institute for Cancer Research
Northern Institute for Cancer Research
NGNoah Gorelick
Noah Gorelick
RRRuman Rahman
Ruman Rahman
Purpose: High-grade glioma (HGG) treatment is limited by the inability of otherwise potentially efficacious drugs to penetrate the blood–brain barrier. We evaluate the unique intracavity delivery mode and translational potential of a blend of poly(DL-lactic acid-co-glycolic acid; PLGA) and poly(ethylene glycol; PEG) paste combining temozolomide and etoposide to treat surgically resected HGG. Experimental Design: To prolong stability of temozolomide prodrug, combined in vitro drug release was quantitatively assessed from low pH–based PLGA/PEG using advanced analytic methods. In vitro cytotoxicity was measured against a panel of HGG cell lines and patient-derived cultures using metabolic assays. In vivo safety and efficacy was evaluated using orthotopic 9L gliosarcoma allografts, previously utilized preclinically to develop Gliadel. Results: Combined etoposide and temozolomide in vitro release (22 and 7 days, respectively) was achieved from a lactic acid–based PLGA/PEG paste, used to enhance stability of temozolomide prodrug. HGG cells from central-enhanced regions were more sensitive to each compound relative to primary lines derived from the HGG-invasive margin. Both drugs retained cytotoxic capability upon release from PLGA/PEG. In vivo studies revealed a significant overall survival benefit in postsurgery 9L orthotopic gliosarcomas, treated with intracavity delivered PLGA/PEG/temozolomide/etoposide and enhanced with adjuvant radiotherapy. Long-term survivorship was observed in over half the animals with histologic confirmation of disease-free brain. Conclusions: The significant survival benefit of intracavity chemotherapy demonstrates clinical applicability of PLGA/PEG paste-mediated delivery of temozolomide and etoposide adjuvant to radiotherapy. PLGA/PEG paste offers a future platform for combination delivery of molecular targeted compounds.


31 March 2023
Verified
Other
Open access
ASand Stuart Smith
and Stuart Smith
BTBetty M. Tyler
Betty M. Tyler
TGToby Gould
Toby Gould
Northern Institute for Cancer ResearchNorthern Institute for Cancer Research
Northern Institute for Cancer Research
NGNoah Gorelick
Noah Gorelick
RRRuman Rahman
Ruman Rahman
Supplementary Figure 2 and Legend

31 March 2023
Verified
Other
Open access
ASand Stuart Smith
and Stuart Smith
BTBetty M. Tyler
Betty M. Tyler
TGToby Gould
Toby Gould
Northern Institute for Cancer ResearchNorthern Institute for Cancer Research
Northern Institute for Cancer Research
NGNoah Gorelick
Noah Gorelick
RRRuman Rahman
Ruman Rahman
Supplementary Figure 4 and Legend